Point72 DIFC Ltd Takes $3.12 Million Position in ICU Medical, Inc. (NASDAQ:ICUI)

Point72 DIFC Ltd bought a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 17,100 shares of the medical instruments supplier’s stock, valued at approximately $3,116,000. Point72 DIFC Ltd owned about 0.07% of ICU Medical at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd acquired a new stake in ICU Medical during the third quarter worth approximately $72,000. Captrust Financial Advisors raised its stake in ICU Medical by 54.2% in the third quarter. Captrust Financial Advisors now owns 2,969 shares of the medical instruments supplier’s stock valued at $541,000 after purchasing an additional 1,043 shares in the last quarter. Martingale Asset Management L P acquired a new position in shares of ICU Medical in the 3rd quarter valued at approximately $255,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in ICU Medical by 4.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,742 shares of the medical instruments supplier’s stock worth $7,788,000 after purchasing an additional 1,751 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its stake in shares of ICU Medical by 15.1% in the 3rd quarter. Public Sector Pension Investment Board now owns 51,854 shares of the medical instruments supplier’s stock valued at $9,449,000 after purchasing an additional 6,800 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ICUI has been the subject of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. Jefferies Financial Group began coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price on the stock. Raymond James raised their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. KeyCorp lifted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Finally, StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total transaction of $1,954,920.00. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $17,039,245.63. The trade was a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 1,962 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $169.08, for a total transaction of $331,734.96. The disclosure for this sale can be found here. Insiders sold 40,364 shares of company stock valued at $6,869,878 in the last 90 days. Insiders own 6.70% of the company’s stock.

ICU Medical Trading Down 2.7 %

Shares of ICUI opened at $156.64 on Wednesday. The firm has a market cap of $3.83 billion, a price-to-earnings ratio of -34.28 and a beta of 0.62. The firm has a 50 day moving average price of $173.90 and a 200-day moving average price of $148.43. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. ICU Medical, Inc. has a fifty-two week low of $83.26 and a fifty-two week high of $196.26.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.